A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Diagnosis of rheumatoid arthritis according to ACR/EULAR classification (2010) of \>/= 6 months duration * Active moderate to severe rheumatoid arthritis (DAS \>/= 3.2) * Swollen joint count (SJC) \>/= 6, tender joint count \>/= 8 * Synovitis in the dominant hand * Inadequate response to stable dose of a non-biological DMARD for at least 3 months * Oral corticosteroids must have been on stable dose for at least 25 out of 28 days before first dose of study drug * Patient on outpatient treatment Exclusion Criteria: * Major surgery (including joint surgery) in the 8 weeks prior to screening, or planned major surgery within 6 months of randomization * Rheumatic autoimmune disease other than rheumatoid arthritis * American College of Rheumatology (ACR) functional class IV * History of or current inflammatory joint disease other than rheumatoid arthritis * Previous inadequate response to a biologic DMARD; prior biologic therapy for no longer than 1 month is allowed if discontinued for reasons of tolerability at least 6 months prior to study recruitment * Intra-articular or parenteral corticosteroids within 6 weeks prior to study start * Inadequate hematologic, renal or liver function * Positive for hepatitis B, hepatitis C or HIV infection * Pregnant or lactating women * History of severe allergic reactions or anaphylaxis to human, humanized or mural monoclonal antibodies * Current infections or history of recurrent infections * History of or currently active primary or acquired immunodeficiency * Active tuberculosis requiring treatment in the previous 3 years * Body weight \> 150 kg